Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma.

Multiple myeloma (MM) is a hematological malignancy and poses significant therapeutic challenges. This review synthesizes evidence from pivotal clinical trials to guide induction treatment for transplant-eligible (TE), newly diagnosed MM (NDMM) patients. Emphasizing the evolution from three-drug to four-drug induction therapies, we highlight the integration of monoclonal antibodies, particularly CD38 recombinant monoclonal antibody agents, into treatment regimens.

New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma.

Introduction: Non-Hodgkin lymphomas (NHLs) encompass a wide range of diseases from precancerous states such as monoclonal B-cell lymphocytosis to the rapidly growing Burkitt lymphoma. In 2022, we witnessed two new classifications for these malignant lymphoid tumors: The World Health Organization (WHO) 5th edition Classification of Haematolymphoid Tumours and the International Consensus Classification of Mature Lymphoid Neoplasms (ICC).

Areas Covered: Given our improved understanding of the mechanisms underlying lymphomagenesis at the molecular level, several novel agents have been or are being actively developed, including targeted therapies and immunotherapies.

CHANGES IN THE SERUM LEVEL OF LEPTIN AND TRANSFORMING GROWTH FACTOR-Β1 IN PATIENTS WITH ARTERIAL HYPERTENSION ON A BACKGROUND OF ABDOMINAL OBESITY.

Objective: The aim: Study of the levels of leptin and the growth modulator TGF-β1 in the blood serum of patients with hypertension, which occurs on the background of AO and without it.

Patients And Methods: Materials and methods: Carbohydrate metabolism was studied by the enzymatic method, the level of insulin in the blood (by the enzyme immunoassay method), the oral glucose tolerance test and the calculation of the NOMA index.

Results: Results: The data obtained in the work indicate a significant role of leptin in the formation of hypertension itself and the development of obesity, carbohydrate and lipid metabolism disorders.

THE RELEVANCE OF THE DEVELOPMENT AND IMPLEMENTATION OF QUALITY SYSTEM IN CLINICAL DIAGNOSTIC LABORATORIES.

Objective: The aim: To analyze the implementation of international standards ISO series, which ensures the creation of uniformity of measurements, the ability to use the results of laboratory studies to ensure their reliability and reproducibility.

Patients And Methods: Materials and methods: The samples were taken from the ISO documents, the Regulation and the Quality Decree of clinical diagnostic laboratory (2017) that is the object of the research activities of the clinical diagnostic laboratory "City clinical hospital № 2 named after Prof. A.

Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction.

The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD). A total of 48 patients with grade 2-3 AH and HHD at the age of 52.23 ± 7.